Legal Representation
Attorney
Andrew D. Price & Paula E. Hopkins
USPTO Deadlines
Next Deadline
1238 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-11-27)
Due Date
November 27, 2028
Grace Period Ends
May 27, 2029
Application History
24 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 8, 2025 | ES8R | I | TEAS SECTION 8 RECEIVED |
| Nov 20, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Nov 27, 2023 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Dec 28, 2022 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Nov 27, 2018 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Sep 26, 2018 | ISPO | Z | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST |
| Sep 26, 2018 | 1.BD | I | Sec. 1(B) CLAIM DELETED |
| Sep 24, 2018 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED |
| Sep 11, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 11, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 22, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 6, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 6, 2018 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Aug 6, 2018 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Aug 6, 2018 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Aug 6, 2018 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Aug 1, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| May 10, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 10, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 9, 2018 | ALIE | A | ASSIGNED TO LIE |
| May 2, 2018 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| May 2, 2018 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Apr 22, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Apr 17, 2018 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy for the treatment of tumorous diseases and autoimmune diseases
Classification
International Classes
005